Reference Molecule Number of patients Polymorphism Vs. normal control F/U duration (months) Renal progression Biology Lim et al. [22] Clara cell secretory protein N = 267 G38A No difference 103.8 ± 52.6 AA genotype…
Family history 1992–2000 2001–2010 With GN 95/908 (10.5 %) 77/822 (9.5 %) With dialysis 42/908 (4.6 %) 58/822 (7.1 %) Number of positive case/total number (%) Clinical phenotype of familial IgAN is generally similar…
Fig. 8.1 Answers selected by the audience for Case 1 In January 2014, BP 124/68, proteinuria 1.5 g/day, urinary RBC 5-9/HPF, eGFR 55 mL/min/1.73 m2. Renal biopsy: acute lesion (endocapillary hypercellularity) (+), chronic…
© Springer Japan 2016Yasuhiko Tomino (ed.)Pathogenesis and Treatment in IgA Nephropathy10.1007/978-4-431-55588-9_18 18. Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients Yusuke Suzuki1 , Rosanna Coppo2 and Yasuhiko Tomino1 (1) Division of Nephrology,…
Year 1977 1983 1985 1988–1989 1997 2005 2006 Author [Ref] Ueda [1] Kitajima [2] Glassock [3] Yoshikawa [4] Koyama [5] Nozawa [9] Wakai [7] Source of patients Tokyo Jikei U…
Recommendation Long-term ACEI or ARB or ARB treatment when proteinuria is >1 g/day, with up-titration of the drug depending on blood pressure (1B) Suggestions Proteinuria ACEI or ARB if proteinuria is…
Authors Proposed target proteinuria Study design and characteristics of the cohort Partial remission or clinical remission Definition of proteinuria remission, g/day Timing of proteinuria measurements taken as a surrogate marker…
Fig. 2.1 Surface interpolation of the standardized genetic risk score over Africa and Euroasia (main) and the Americas (inset). Symbols represent the locations of sampled populations [164] 2.3.4 Shared Genetics…
Chapter Recommendation statement Grade 10.2 Antiproteinuric and antihypertensive therapy 10.2.1 We recommend long-term ACEI or ARB treatment when proteinuria is >1 g/day, with up-titration of the drug depending on blood pressure…
© Springer Japan 2016Yasuhiko Tomino (ed.)Pathogenesis and Treatment in IgA Nephropathy10.1007/978-4-431-55588-9_13 13. Differences in Etiology and Treatment in Scandinavian Countries Jukka Mustonen1, 2 , Kati Kaartinen3, Jaana Syrjänen2 and Ilkka Pörsti1, 2 (1) School of Medicine, University of Tampere,…
